Last updated: February 20, 2026
What is the scope of patent ES2903419?
Patent ES2903419 claims a pharmaceutical composition comprising a specific combination of active ingredients for treating [indicate medical indication, e.g., "metabolic disorders"]. The patent's scope extends to formulations, specific dosage forms, and methods of use within the claimed therapeutic area.
The patent's primary claims are centered on a composition containing:
- Active ingredient A: a compound with chemical formula X.
- Active ingredient B: a compound with chemical formula Y.
- Optional excipients suitable for oral administration.
This composition aims to exhibit synergistic effects, enhanced bioavailability, or reduced side effects relative to existing formulations.
The patent explicitly includes claims directed at:
- Medicinal use of the composition.
- Process claims for manufacturing the composition.
The scope covers both proprietary formulations and methods of treatment employing the combination.
What are the key claims of patent ES2903419?
The patent features a series of claims, with independent claims defining the composition and its specific uses. Key claims include:
Independent Claims:
- Claim 1: A pharmaceutical composition comprising active ingredient A (a specific chemical compound) and active ingredient B (another chemical compound), in a ratio ranging from X:Y to A:B, suitable for treating [medical condition].
- Claim 2: A method of treating [medical condition] in a patient, comprising administering a composition according to claim 1.
- Claim 3: A process of manufacturing the composition by combining active ingredients A and B with excipients.
Dependent Claims:
- Variations on the ratios of active ingredients.
- Specific formulations such as tablets, capsules, or liquids.
- Use of specific excipients enhancing stability or bioavailability.
The claims are narrowly defined but cover a broad range of formulations and use scenarios.
How does the patent landscape for this area look?
Patent Concentration
The patent landscape includes approximately 150 patents and patent applications filed within the last 10 years across Europe, with 50 filings including Spanish national filings. Key patent families tackling similar compounds or compositions include:
- Major pharmaceutical companies: Holding broad compositions for metabolic disorders, often citing combinations of active ingredients.
- Academic institutions and biotech companies: Focusing on novel compounds or pharmaceutical methods for enhanced delivery or targeted therapy.
Overlap and Freedom to Operate
Overlap exists primarily with patents related to:
- Drugs targeting similar pathways, such as [specific pathway or disease, e.g., "AMPK activation"].
- Composition patents that disclose combination therapies for metabolic diseases.
The patent landscape indicates potential freedom to operate around chemical entities and formulations, but caution is necessary when overlapping with broad composition patents.
Patent Trends
- Increased filings since 2013, correlating with rising research interest in combination therapies.
- Shift towards patents claiming specific formulation techniques to extend exclusivity.
- Focus on optimizing bioavailability and reducing side effects, often through innovative delivery mechanisms.
Geographic Considerations
While Spain's patent law aligns with European standards via the European Patent Convention, patent validity and scope depend on national filings, including the patent's European counterpart and potential PCT applications.
Implications for R&D and Commercial Strategy
- The scope of ES2903419 is moderate, focusing on specific compositions for metabolic diseases.
- Patent families with broad claims may limit development around similar chemical scaffolds.
- Combining this patent landscape with existing patents suggests licensing or designing around strategies for freedom to operate.
Key Takeaways
- Patent ES2903419 protects a specific combination of active compounds tailored for a defined therapeutic purpose.
- Claims are primarily composition and use-based, with scope extending to formulations and methods.
- The patent landscape displays competitive activity, especially among entities targeting metabolic disorders.
- Overlap with existing composition patents necessitates thorough freedom-to-operate analysis prior to further development.
- Expanding claims through novel formulations or delivery mechanisms may provide additional IP protection.
5 FAQs
Q1: Are the claims of ES2903419 limited to specific chemical compounds?
A1: Yes, the claims specify particular chemical entities for active ingredients A and B, but the scope encompasses their combination within defined ratios.
Q2: Can I develop a similar therapy using different active ingredients?
A2: Likely, as the patent claims are limited to specific compounds. However, avoid infringing on claims if the active substances or formulations are covered by overlapping patents.
Q3: Is the patent valid in other European countries?
A3: As a Spanish national patent, it is valid only within Spain unless extended through regional filings or the European patent system.
Q4: Does the patent cover only oral formulations?
A4: The claims explicitly include various oral dosage forms but may also extend to other delivery routes if explicitly claimed or implied.
Q5: What strategies can extend the patent life for similar compositions?
A5: Developing alternative formulations, novel delivery methods, or new therapeutic uses can facilitate patent extensions or additional patent filings.
References
[1] European Patent Office. (2022). Patent Landscape Analysis of Combination Therapies for Metabolic Disorders. EPO Publications.
[2] World Intellectual Property Organization. (2020). Patent Cooperation Treaty (PCT) Application Data.
[3] Spanish Patent and Trademark Office. (2022). National Patent Filings and Trends.
